|
04 Oct 2019 |
Arbutus Announces Decision to Discontinue Development of AB-506, an Oral Capsid Inhibitor for the Treatment of Chronic Hepatitis B
|
|
04 Oct 2019 |
Fulcrum Therapeutics Announced Results of Phase 1 Clinical Trial of Losmapimod in FSHD
|
|
04 Oct 2019 |
Janssen Submits Supplemental New Drug Application to U.S. FDA for SPRAVATO® (esketamine) CIII Nasal Spray for the Rapid Reduction of Depressive Symptoms in Adults with Major Depressive Disorder Who Have Active Suicidal Ideation with Intent
|
|
04 Oct 2019 |
Milestone Pharmaceuticals Announces First Patient Enrolled in NODE-303 Open-label Safety Study of Etripamil in PSVT
|
|
04 Oct 2019 |
Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for Niraparib for the Treatment of Metastatic Castration-Resistant Prostate Cancer
|
|
04 Oct 2019 |
PTC Therapeutics Announces New Real-World Analysis Demonstrating Translarna™ (ataluren) Slows Disease Progression in Patients with Duchenne Muscular Dystrophy
|
|
04 Oct 2019 |
Graybug Vision Initiates Phase 2b (ALTISSIMO) Clinical Trial of GB-102 in Patients with Wet Age-Related Macular Degeneration
|
|
04 Oct 2019 |
FDA Approves Labeling Supplement for Puma Biotechnology’s NERLYNX® (neratinib) for the Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
|
|
04 Oct 2019 |
Aeovian Pharmaceuticals Raises $37 Million Series A Financing to Advance Selective mTORC1 Inhibitors into the Clinic for Rare and Age-Related Diseases
|
|
04 Oct 2019 |
U.S. Food and Drug Administration Approves Descovy® for HIV Pre-Exposure Prophylaxis (PrEP)
|
|
03 Oct 2019 |
Athira Pharma Announces Completion of Phase 1b Clinical Trial of NDX-1017 in Alzheimer's Patients
|
|
03 Oct 2019 |
Risdiplam Spinal Muscular Atrophy Data Demonstrating Continued Benefit Presented at World Muscle Society Congress
|
|
02 Oct 2019 |
Shionogi Reports Positive Results from Cefiderocol Phase III Study in Adults with Pneumonia Caused by Gram-negative Pathogens
|
|
02 Oct 2019 |
Update on US regulatory review of PT010 in COPD
|
|
02 Oct 2019 |
NCX 470 met the primary endpoint of non-inferiority and also demonstrated superiority to latanoprost, the U.S. market leader in prostaglandin analog prescriptions, in multiple pre-specified analyses
|
|
01 Oct 2019 |
Lilly Announces Positive Registrational Data for Selpercatinib (LOXO-292) in Heavily Pretreated RET-Altered Thyroid Cancers
|
|
01 Oct 2019 |
Debiopharm's Novel IAP Antagonist Debio 1143 Achieves Outstanding Phase II Results for High-Risk Head and Neck Cancer Patients
|
|
01 Oct 2019 |
New Data Presented at ESMO Congress 2019 from the Arginase Inhibitor INCB001158 Alone and in Combination with Pembrolizumab
|
|
01 Oct 2019 |
GARDP and Entasis Therapeutics Initiate Global Phase 3 Trial of Zoliflodacin, a First-in-Class Oral Antibiotic for the Treatment of Gonorrhea
|
|
01 Oct 2019 |
Basilea reports at ESMO meeting that drug candidate derazantinib showed clinical benefit in intrahepatic cholangiocarcinoma (iCCA) patients with various FGFR2 genetic aberrations
|
|
01 Oct 2019 |
Novartis announces positive results from Phase III IRIDIUM study of inhaled combination QVM149 in patients with uncontrolled asthma
|
|
01 Oct 2019 |
Novartis announces positive results from Phase III PALLADIUM study of inhaled combination QMF149 in patients with uncontrolled asthma
|
|
01 Oct 2019 |
ORYZON Presents Positive Efficacy Results on Iadademstat in ED-SCLC Patients at ESMO-2019
|
|
01 Oct 2019 |
Turning Point Therapeutics Announces FDA Clearance of Investigational New Drug Application for TPX-0046, a Novel RET/SRC Inhibitor
|
|
01 Oct 2019 |
Data from Agios’ Phase 3 ClarIDHy Trial of TIBSOVO® Demonstrates Significant Improvement in Progression Free Survival (PFS) Compared to Placebo in Previously Treated IDH1 Mutant Cholangiocarcinoma Patients
|
